Adjuvant Chemotherapy Improves Survival in Resected Early-onset Pancreatic Cancer after Neoadjuvant Therapy: A Retrospective Cohort Study Based on the SEER Database
The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear. While adjuvant chemotherapy (ACT) has shown survival benefits in pancreatic ductal adenocarcinoma, its specific role in EOPC patients following neoadjuvant chemotherapy (NACT) and surgery remains underexplored. This study aimed to assess the clinical benefit of ACT in EOPC patients after NACT.
Authors
- Hanlin Yin (ORCID: https://orcid.org/0000-0002-6622-4301)
- Wenhui Lou (ORCID: https://orcid.org/0000-0001-5820-6843)
- Zhihang Xu
- Qiangda Chen (ORCID: https://orcid.org/0000-0003-0428-5173)
- Taochen He
- Joseph R. Habib (ORCID: https://orcid.org/0000-0003-3445-2278)
- Ning Pu (ORCID: https://orcid.org/0000-0002-3123-493X)
- Wenchuan Wu (ORCID: https://orcid.org/0000-0001-6317-3417)
- Yun Jin (ORCID: https://orcid.org/0000-0001-7750-1370)
- Liang Liu
- Zhenlai Jiang
Publication Details
- Journal
- Oncology Advances
- Published
- 2025-06-06
- DOI
- https://doi.org/10.14218/ona.2025.00008
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Anti-Cancer Association
- Shanghai Municipal Health Commission
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Program of Shanghai Academic Research Leader